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CHAPTER 1. GENERAL INTRODUCTION 
Literature Review 
Alzheimer's disease (AD) is a progressive neuronal degenerative disorder that results in 
a loss of higher cognitive function. The histopathologic changes of AD are relatively 
stereotyped; the hallmark of AD is a loss of neurons and synapses accompanied by a gradual 
accumulation of p-amyloid plaques, neuritic plaques, neurofibrillary tangles, and dystrophic 
neurites®® ®'. Recent interest has been directed toward p-amyloid (pi-42), the primary protein 
component of the neuritic plaques^'®. According to the 'amyloid theory,' it is this peptide 
which is responsible for initiating and promoting AD. It is important to note that p-amyloid 
deposition can occur in the absence of neuronal degeneration in patients with AD. Non-
compacted, diffuse deposits of p-amyloid are not always associated with dystrophic neurites. 
In contrast, the dense-core type (or matured) amyloid plaque is almost always associated with 
dystrophic neurites that often contain paired helical filaments or show abnormal 
immunoreactivity to the tau protein*®"'. These observations suggest that neuritic plaques 
progress from a diffuse inert form to a p-pleated p-amyloid plaque accompanied by dystrophic 
neurites. To date, however, the effects of namrally occurring p-amyloid on the cells of the 
central nervous system have not been determined. 
When p-amyloid plaque cores, isolated from AD tissue, were injected into the 
hippocampus of rats, neuronal loss was observed by one month post-injection". Furthermore, 
the in vitro study using the cerebral cortex of Alzheimer's patients as a substratum 
demonstrated that the survival of rat hippocampal neurons was significady reduced in the peri-
plaque region^. Although the brain tissue used for intrahippocampal injection or substrate for 
cultured cells contained all of the constiments of plaques, not just amyloid, it is suggestive that 
P-amyloid from AD tissue has neurotoxic properties. In contrast, synthetic p-amyloid directly 
injected into the brain of experimental animals failed to induce consistent neurotoxic 
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Since in vitro studies suggest that the soluble P-amyloid monomer requires 
conversion to a largely p-pleated sheet conformation and aggregation into a fibrillar form before 
it can confer neurotoxicity'®"^'*, it is unlikely that neurotoxic effects of synthetic p-amyloid 
would be seen immediately, if ever. Unfortunately, these studies were based on a short-term 
survival period (7 days and 3 months post-injection in rat and monkey experiments, 
respectively). A longer post-injection time period may be needed to induce specific 
neurodegenerative changes in vivo. For example, it required 4 months before specific 
neurodegenerative changes could be observed in the rat following transplantation of transfected 
PC 12 cells that produce PAPP-CI04 (i.e., the carboxyl-terminal 104 amino acids of the 
amyloid precursor protein)"*^. Since the development of AD seems to follow many years of 3-
amyloid deposition and a prolonged preclinical period^, it is likely that the current experimental 
approach of intracerebral injection of p-amyloid does not exacdy simulate the pathogenesis of p-
amyloid in vivo. 
Whether and how p-amyloid is neurotoxic under biologically relevant experimental 
conditions has been the subject of intense study. Studies carried out in cell culmre using 
neurons derived from fetal rats produce a somewhat confusing picmre of synthetic p-amyloid 
neurotoxicity. Whitson et al.^ demonstrated that a peptide homologous to the first 28 amino 
acids of p-amyloid (i.e., pi-28) induces neurotrophic activity in hippocampal neurons. 
Subsequently, it was shown that the fiill length P-amyloid peptide (pi-42) increased neurite 
length and branching^'. These results contrast with research by Yankner et al.®^ who reported 
that fragments of p-amyloid, as well as the complete peptide sequence, p 1 -40, were neurotoxic 
to hippocampal cells in primary culmre. Whether p-amyloid exerts trophic or toxic effects on 
cultured neurons seems to depend on the stage of neuronal differentiation in culture". It was 
shown that pi-40 was neurotrophic only during the early stages of differentiation (days 0-2 
post-plating) and that pi-40 induced degeneration of differentiated neurons (days 3-5 post-
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plating). In contrast, a study by Pike et al/® showed that neurons at the early stages of 
differentiation undergo neurodegeneration if exposed to aggregated p-amyloid. 
Obviously, most of the previous studies regarding p-amyloid and AD have been 
focused on the direct neuronal effects of p-amyloid; however, the morphological observation of 
diffuse, putatively 'early' neuritic plaques and classic plaques suggests that reactive glial cells 
are a prominent component of the neuritic plaques. Reactive cells associated with neuritic 
plaques include microglia, astrocytes, and T-cells"""^. It has been suggested that glial cells 
surrounding neuritic plaques are involved in the removal of debris from degenerated 
neurites^"-^ or in the synthesis and deposition of p-amyloid®'. However, nearly all classic 
plaques have HLA-DR-positive microglial cells^". T-cells, which are often difficult to 
distinguish from glial cells under routine histological stains, are also identified by 
immunocytochemistry"*". Also present at high levels in the plaques are cell adhesion molecules 
such as P2 integrins^" ', as well as cytokines such as IL-1 and TGF-p^ "''^^. It is possible that 
these elements of the neuritic plaque are in some way responsible for the manner in which 
neurons degenerate. 
Recent in vitro studies suggest that p-amyloid, directly or indirectly, can induce 
oxidative injury mediated by the formation of free-radicals and hydrogen peroxide"''^^", 
suggesting oxidative damage as a potential cause of neuronal degeneration. Reactive microglial 
cells are known to release the free radical nitric oxide which has been shown to be toxic to 
neurons" ®'. Nitric oxide binds avidly to the iron-sulphur centers of enzymes, including 
enzymes involved in the mitochondrial electron transport chain, the citric acid cycle, and DNA 
synthesis"'. Nitric oxide also reacts with superoxide anions to form peroxynitrite anions that 
decompose to yield highly damaging hydroxyl free radicals and nitrogen dioxide\ Neurons 
seem to be especially vulnerable to oxidative stress and free-radical damage since they contain 
low levels of glutathione, a major antioxidant that is responsible for removal of cytosolic 
peroxides". Microglial release of nitric oxide accompanied by a marked reduction in neuronal 
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cell survival in vitro suggests significant implications of nitric oxide on CNS pathophysiology, 
given the anatomical location and abundance of microglial cells, and the wide variety of 
potential interactions that nitric oxide can have with cellular biochemistry. Microglial release of 
free radicals may also alter neuronal effects of p-amyloid, since oxidation of p-amyloid by free 
radicals can also generate insoluble protein aggregations 
The mechanisms involved in microglial stimulation for release of nitric oxide are not 
well understood. What is known is that microglial nitric oxide synthase (NOS) appears to 
catalyze the same reaction as the neuronal NOS and requires nicotinamide adenine dinucleotide 
phosphate (NADPH) and flavin adenine dinucleotide (FAD), but it is calcium- and calmodulin-
independent and must be induced by agents such as bacterial cell wall lipopolysaccharide (LPS) 
or interferon-y (IFN-y)®'®^ '"*". In regard to p-amyloid, it was shown that peritoneal 
macrophages, widiout priming with IFN-y respond to pi-40, but not to P25-35, by releasing 
nitric oxide^. 
Whether p-amyloid is responsible for the activation of microglia and subsequent release 
of nitric oxide has not been elucidated. Furthermore, the mechanism by which p-amyloid-
mediated release of microglial nitric oxide might occur remains unknown. Previous studies 
have shown that engagement of the surface receptor Mac-1 may be required for the maximum 
respiratory burst response of macrophages and polymorphonuclear cells'- ""-^-'®. Mac-1 
belongs to a family of adhesion molecules composed of a heterodimer between an a and p-
subunit found almost exclusively on leukocytes or cells of this lineage^. Each of these 
adhesion molecules shares an identical p subunit (CD 18), and they are distinguished by their a 
subunits designated CDlla, CDllb, and CDllc for LFA-la, Mac-la, and pl50,95a, 
respectively. Mac-1 (CDl lb/CD 18) is the CR3 receptor and binds, most importantly. C3bi and 
CD54 (ICAM-1). 
Microglial cells express Mac-1 that consists of an cm chain noncovalently associated 
with a P2-chain"^. Although Mac-1 and its subunit p2 are upregulated in reactive microglial cells 
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associated with neuritic plaques^® ', its role in brain function is not clear. The ftinction of p2-
integrins and Mac-1 in cell adhesion has been demonstrated from the defects displayed by 
polymorphonuclear (PMN) leukocytes of children with leukocyte adhesion deficiency (LAD), 
cattle with LAD, or by normal PMN treated with anti-fo or anti-Mac-1 antibodies^~•"••*^ PMN 
in LAD patients migrate poorly through tissues to sites of inflammation, and like normal PMN 
treated with antibodies directed against the P2-integrins, PMN in LAD patients attach and 
spread poorly in vitro. Numerous ligands for Mac-1 have been identified, including: C3bi. 
ICAM-1, coagulation factor X, and fibrinogen^. The binding sites for those have been mapped 
to the a-chain". It has also been shown that Mac-1 adheres more rapidly and extensively on 
substrates coated with denatured protein than native protein'". Therefore, Mac-1 plays an 
important role in cell-cell and cell-matrix interactions^. 
Mac-1 was shown to have two binding sites, one for peptide and a second for lipids", 
and the maximum respiratory burst response or nitric oxide release of macrophages and PMN 
requires the synergistic action of IFN-y and These observations suggest that 
Mac-1 can mediate a co-stimulatory signal in a variety of cells. Although litde is known about 
the mode of action of Mac-1 in response to stimulatory signals, it has been shown, in 
monocytes, that binding to CDl lb of Mac-1 not only increases binding of ligands to CD-18, 
but also induces an optimal respiratory burst and release of hydrogen peroxide from 
macrophages by ligation of CD 18Recently it was reported that antibody to Mac-ip was 
found to stimulate nitric oxide production and inducible nitric oxide synthase mRNA 
expression in alveolar macrophages"**. This is the first report of a connection between Mac-I 
and nitric oxide release from a macrophage. 
In summary, microglial cells have been shown to nslease nitric oxide that is toxic to 
neurons"'^^. Nitric oxide release by microglia in response to p-amyloid (P25-35) may require, 
or may be enhanced by, co-exposure to any number of co-stimulatory factors, i.e. IFN-o/p, 
IFN-y. TNF-a. TNF-|J. or IL-1. Co-stimulatory factors are a common requirement for cells 
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of macrophage lineage when induction of respiratory burst activity, or nitric oxide production 
via the Mac-1 receptor, is necessary'® '". Therefore, the Mac-1 receptor, known to be present 
on the cell surface of brain microglia', is a likely candidate through which ^amyloid can 
induce nitric oxide release in microglial cells. Understanding the way in which p-amyloid 
affects microglial release of nitric oxide should be critical for studying the role of microglial 
cells in the pathogenesis of neuronal degeneration in AD. 
Research Objective 
While previous studies on the neurodegeneration of Alzheimer's disease (AD) have 
focused predominandy on neuronal cells and direct 3-amyloid-mediated neurotoxicity, few 
have sought to elucidate the role of reactive glial cells in the disease process. The purpose of 
the research in this dissertation is to examine the effects of p-amyloid on nitric oxide release 
from cultured microglia and to characterize a mechanism by which p-amyloid might act to exert 
such an effect. The extent to which p-amyloid affects nitric oxide release from microglia will be 
assessed by observing changes in microglial morphology, nitric oxide synthase activity, and 
nitric oxide release from microglia exposed to ^amyloid (P25-35 and pi-40) alone and in 
combination with the co-stimulatory factors IFN-o/p, EL-lp, TNF-a, TNF-P , and IFN-y. 
Once the effect of p-amyloid on nitric oxide release from microglia has been characterized, a 
potential receptor through which p-amyloid might act will be studied. The interaction of p-
amyloid (p25-35) and the microglial P2 integrin receptor, Mac-1, will be smdied by (1) 
assessing the suppressive effects of anti-Mac-1 monoclonal antibodies (mAbs) on p-amyloid-
mediated release of microglial nitric oxide and (2) assaying competiuve binding of biotinylated 
pi-42 and anti-Mac-1 mAbs to microglial cells by immunofluorescent flow cytometry. The 
results of the research in this dissertation support a role for microglia in the neurodegeneration 
of Alzheimer's disease via nitric oxide toxicity induced by the synergistic action of p-amyloid 
with a co-stimulatory factor and mediated through the microglial surface receptor Mac-!. 
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Dissertation Organization 
This dissertation was prepared in accordance with the Iowa State University Graduate 
College Thesis Manual for the inclusion of papers in a thesis. Following the Table of Contents 
and General Introduction, two papers are presented. The first paper has been published in 
Brain Research vol. 692 (1995) 207-214. The second paper is currendy being submitted for 
publication to a journal in the field of neuroscience. After the second paper, a General 
Discussion section is presented which addresses the findings of both papers. Figures and 
tables are presented at the end of each paper. Reference sections are presented at the end of 
each chapter and include references pertaining to that chapter. 
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CHAPTER 2. MICROGLIAL RELEASE OF NITRIC OXIDE BY THE 
SYNERGISTIC ACTION OF p-AMYLOID AND EFN-y 
' A paper published in Brain Research 
^Jeffrey L. Goodwin, ^Etsuro Uemuraand "^Joan E. Cunnick 
Summary 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized 
histopathologically by a loss of neurons and an accumulation of p-amyloid plaques, 
neurofibrillary tangles, dystrophic neurites, and reactive glial cells. While most previous 
studies on the neurodegeneration of AD have focused on neuronal cells and direct p-amyloid-
mediated neurotoxicity, few have focused on the role of reactive glial cells in 3-amyloid-
mediated neurotoxicity. In the present study nitric oxide release from culmred rat microglia 
was examined by exposing the cells to synthetic p-amyloid peptides (P25-35 and pi-40) alone 
and in combination with the cytokines IFN-a/p (100 U/ml), IL-ip (100 U/ml), TNF-a (100 
U/ml), TNF-P (100 U/ml), or IFN-y (10, 100, 500, or 1000 U/ml). Assessment of microglial 
release of nitric oxide was based on the colorimetric assay for nitrite in the culture medium and 
histochemistry for niuic oxide synthase. Of the cytokines tested, only IFN-y (1000 U/ml) 
induced nitric oxide release from microglia. P25-35 did not stimulate nitric oxide release by 
itself, but it did induce nitric oxide release when co-exposed with IFN-y (100, 500, and 1000 
U/ml). In contrast, pi-40 did induce microglial release of nitric oxide by itself, and this effect 
was enhanced significantly by co-exposure with IFN-y (100 U/ml). These findings warrant a 
further investigation into the role of microglia in the neurodegeneration of Alzheimer's disease 
' Reprinted with permission of Brain Research 692 (1995) 207-214 
- Dcpartmeni of Anatomy. Iowa State University, Ames. lA 50011. USA 
•' Department of Anatomy, Iowa State University. Ames. lA 50011, USA; Author for correspondence 
^ Department of Microbiology. Immunology and Preventative Medicine, Iowa State University. Ames. lA 
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via nitric oxide toxicity induced by the synergistic action of |J-amyloid and a costimulatory 
factor. 
Introduction 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that results in a 
loss of higher cognitive function. The hallmark of AD is a loss of neurons and synapses 
accompanied by a gradual accumulation of diffuse P-amyloid plaques, neuritic plaques, 
neurofibrillary tangles, and dystrophic neurites^'^^'^^. P-amyloid deposition can occur in 
the absence of neuronal degeneration in patients with AD. Non-compacted, diffuse (or early) 
deposits of p-amyloid are not always associated with dystrophic neurites and reactive 
astrocytes. In contrast, the dense-core type (or mamred) neuritic plaques are almost always 
associated with dystrophic neurites, reactive microglia and astrocytes 9. These 
observations suggest that neuritic plaques progress from the diffuse inert form to the p-pleated 
p-amyloid plaque. To date, the effects of this namrally occurring p-amyloid protein on the cells 
of the central nervous system have not been determined. 
Studies carried out in cell culture produce a somewhat confusing picture of synthetic p-
amyloid neurotoxicity. Whitson et al. (1989)4^ demonstrated that a peptide homologous to the 
first 28 amino acids of p-amyloid (i.e., pi-28) induced neurotrophic activity in hippocampal 
neurons. Subsequently, it was shown that the full length p-amyloid peptide (pi-42) increased 
neurite length and branching'^2 These results contrast with research by Yankner et al. 
(1990)*^^ who reported that fragments of p-amyloid, as well as the complete peptide sequence, 
pi-40, were neurotoxic to hippocampal cells in primary culture. Whether p-amyloid exerts 
trophic or toxic effects on cultured neurons seems to depend on the stage of neuronal 
differentiation^®. It was shown that pi-40 was neurotrophic only during the early stages of 
differentiation (days 0-2 post-plating) and that pi-40 induced degeneration of differentiated 
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neurons (days 3-5 post-plating). In contrast, a study by Pike et al. (1993)^^ showed that 
neurons at the early stages of differentiation undergo neurodegeneration if exposed to 
aggregated P-amyloid. A recent report by Behl et al. (1994)^ showed that p-amyloid induced 
degeneration of susceptible PC 12 cells and rat cortical neurons by hydrogen peroxide-mediated 
lipid peroxidation of cells, suggesting that oxidative damage may be a potential cause of the 
neuronal degeneration in AD. 
Previous studies have focused mainly on the direct neuronal effects of p-amyloid and 
very littie information is available on the glial effects of p-amyloid. Microglia cells, in their 
reactive form, are found closely associated with matured neuritic plaques in the brains of those 
with AD^O. In vitro studies reveal that pi-40 induces proliferation of microglial cells and 
stimulates microglial release of the cytokine interleukin-1 (IL-1)^. This is significant because 
IL-1 levels have been shown to be elevated around the neuritic plaques in AD brains ^ and IL-
1 is known to cause an increase in p-APP mRNA in glia cells and endothelial cells in 
vi7rol0,l 1 
Rodent reactive microglial cells are also known to release the free radical nitric oxide 
which has been shown to be toxic to neurons in ^. Nitric oxide binds to the iron-
sulfur centers of enzymes, thus interfering with the functioning of those enzymes involved in 
the mitochondrial electron transport chain, citric acid cycle, and DNA synthesis Nitric oxide 
also reacts with super oxide anions and forms peroxinitrite anions that decompose to yield 
highly damaging hydroxy! free radicals and nitrogen dioxide^. Microglial release of nitric oxide 
is accompanied by a marked reduction in neuronal cell survival in vitro^. This suggests 
significant implications for nitric oxide in CNS pathophysiology given the anatomical location 
and abundance of microglial cells-^--^ and the wide variety of potential interactions that nitric 
oxide can have with cellular biochemistry. Therefore, the present study was carried out to 
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examine the niicroglial nitric oxide-releasing properties of p-amyloid and various nitric oxide 
synthase inducing cytokines. 
Materials and Methods 
Synthesis of p-amyloid and scrambled peptide: p-amyloid (P25-35) and 
scrambled peptide^S was synthesized by the Iowa State University Protein Facility and purified 
by the Microchemical Facility at the University of Minnesota. The scrambled peptide has the 
following sequence: H-EIe-Met-Leu-Gly-Asn-Gly-Ala-Ser-IIe-GIy-OH. Scrambled peptide, 
P25-35, and pi-40 (Bachem Bioscience Incorporated) were dissolved in sterile tissue culture 
water (Sigma) in a stock concentration of I mg/ml (pH 7.2) and aliquots were stored at -20 °C. 
Microglial culture: Microglia were obtained from the hippocampi of 3-5 day old 
pups (Harlan Sprague-Dawley, Indianapolis, IN). The hippocampi were dissected and the 
cells separated by trypsinization and mechanical dissociation. The cell suspension was diluted 
to 5 ml with MEM culture media supplemented with 10% FBS, 40 mM glucose, 2 mM L-
glutamine, 1 mM pyruvate, 14 mM NaHCOs, 100 lU/ml penicillin, and 100 jxg/ml 
streptomycin. The cell suspension was added to 25 cm^ tissue culture flasks and incubated at 
37 °C in a humidified 5% CO2 atmosphere. After 12-14 days in culture, microglia were 
harvested from the mixed glial culture by gently shaking the flasks, pouring the suspended 
microglia off, and replating them into 24-well Coming Cell Well plates. Purity of the cultures 
was established by observing positive staining with the anti-Mac-1 antibody and negative 
staining with anti-galactocerebroside c (for oligodendrocytes) and anti-glial fibrillary acidic 
protein (for astrocytes). 
Nitric oxide release from microglia in response to p-amyloid was initialy studied using 
the P25-35 peptide. Microglia were plated into 24-well tissue culture plates coated with either 
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P25-35 (50 ^g/welI) or a control peptide (scrambled p25-35; 50 ng/well) and incubated for 4 
days. On post-plating day 1, fresh media (500 nl) alone, or media (500 fil) containing IFN-y 
(10, 100, 500, or 1000 U/ml; GEBCO BRL), IFN-ct/p (100 U/ml; Lee Biomolecular 
Research), IL-ip (1(X) U/ml; Boehringer Mannheim), TNF-a (100 U/ml; Genzyme), or TNF-p 
(100 U/ml; Genzyme), was added to the culture wells. On post-plating day 4, the culture 
supematants were collected for assay of nitric oxide, and the cells were either fixed in 4% 
paraformaldehyde (15 minutes) for NADPH-diaphorase staining or resuspended in EBSS (2 
ml/well) for cellular protein determination. Each experiment was performed in triplicate with 4 
wells per condition per replication. 
A similar protocol was used to study the effects of pi-40 on microglial nitric oxide 
release. Microglia were plated into 24-well tissue culture plates coated with pi-40 and 
incubated for 4 days. On post-plating day 1, fresh media (500 |il ) alone, or media (500 nl ) 
containing IFN-y (100 U/ml), was added to the culture wells. On post-plating day 4, the 
supematants were collected and the cells were processed for NADPH-diaphorase staining or 
protein determination. To examine whether nitrite accumulation in the media in response to pi-
40 was nitric oxide synthase-specific, microglia were exposed to 500 nM N^-Monomethyl-L-
Arginine (NMA) (Calbiochem) to irreversibly inhibit nitric oxide synthase activity. NMA (500 
nM) was added to the culture media immediately post-plating and its presence was maintained 
for the duration of the culture period. Each experiment was performed in triplicate with 4 wells 
per condition per replication. 
Nitric oxide assay: Nitric oxide production was determined indirectly through the 
assay of nitrite (NO2.), a metabolite of nitric oxide, based on the Griess reaction^^. Briefly, a 
sample of the supernatant from each microglia cell condition (500 nl) was mixed with an equal 
volume of Griess reagent (a mixture of 0.1% N-(l-naphthyl)ethylenediamine dihydrochloride 
and 1% sulfanilamide in 2% phosphoric acid), and its absorbance was read on a Roy 
20 
Spectronic 601 spectrophotometer. Nitrite in cell-free medium was determined in each 
experiment and subtracted from the value obtained with cells. Nitrite concentrations were 
calculated from the absorbency values by plotting them on a standard curve established using 
sodium nitrite at known concentrations ranging from 1 to 125 nM. 
Nitric oxide synthase-positive microglia were demonstrated by NADPH-diaphorase 
histochemistry. Briefly, cells were fixed in 4% paraformaldehyde and incubated with 0.1 % 
Triton X-100, O.I mg/ml nitroblue tetrazolium and 1.0 mg/ml p-NADPH in 0.1 M phosphate 
buffer at 3TC for 45 minutes. Cells were then examined under phase contrast and light-field 
illumination for positive (blue/purple) staining. 
Cellular protein assay: Cellular protein concenu^ations in each culture well were 
determined using the Bio-Rad Protein Assay (microassay procedure). Protein concentrations 
were calculated from the absorbency values by plotting them on a standard curve using the 
bovine gamma globulin standard at concentrations ranging from 1 to 25 ng/ml. 
Statistical analysis: All data were analyzed using each litter of rat pups as an 
experimental unit. Data were analyzed for group differences by analysis of variance (ANOVA) 
and significant effects were further analyzed by the t-test. 
Results 
Purity of the microglial cultures, as determined by anti-Mac-1 immunocytochemistry, 
was greater than 95%. A change in morphology was observed in microglial cells culmred on 
P-amyloid substrate. Microglial cells changed from the round, flattened ameboid state (Figure 
lA) to either an elongated, rod-shaped state or a compact, spherical, light refractive ameboid 
state after a few hours in culmre for both P25-35 and pi-40. There was no difference in 
morphology between microglia grown on P25-35 or pi-40 substrate. A significant number of 
21 
microglial ceils exposed to IFN-y (lOOU/ml) became compact, spherical, and light refractive. 
Microglia grown in the presence of both IFN-y and p-amyloid tended to assume the more 
spherical shape, although many rod-shaped cells were still present (Figure IC). 
NADPH-diaphorase staining revealed that morphological changes were not necessarily 
correlated with an increase in nitric oxide synthase activity. Microglial cells with either the 
flattened ameboid shape or the rod shape were mostly negative with the NADPH-diaphorase 
stain in all conditions (Figure IB). Microglial cells with die spherical shape induced by IFN-y 
responded somewhat more frequently to the NADPH-diaphorase stain, usually staining a very 
faint blue color when exposed to IFN-y alone. Exposure to both p-amyloid and IFN-y 
dramatically increased the number and staining intensity of microglial cells positive for 
NADPH-diaphorase (Figure ID). The spherical cells were the cells most intensely stained. 
The number of positive cells in any given well was less than half of the total number of cells in 
each well. 
To determine whether |325-35 alone or in combination with cytokines known to activate 
nitric oxide synthase in cultured glial cells^^, affects microglial release of nitric oxide, nitrite 
levels were measured in the culture media. The cytokines tested were IFN-a/p (100 U/ml), IL-
ip (100 U/ml), TNF-a (100 U/ml), TNF-p (100 U/ml), or IFN-y at various concentrations 
(10, 100, 500, or 1000 U/ml). Table I summarizes these results. Nitrite levels in the 
microglial supernatant were not affected by either control peptide or p25-35 (F=2.658, 
df=2,24, P=0.091). Of the cytokines tested, only IFN-y (lOOU/ml or 500U/ml) in 
combination with P25-35 elicited significant nitrite levels (F=5.692, df=7,16, P=0.002). None 
of the other cytokines induced a significant increase in nitrite levels regardless of the 
experimental condition (F=1.658, df=3,24, P=0.202). 
In subsequent experiments, nitrite levels were more accurately determined by 
considering the possibility that cellular proliferation may have affected the levels of nitrite in the 
culture medium. Cellular protein content was assayed to detect cell proliferation, and microglial 
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release of nitric oxide was expressed as a ratio of nitrite per milligrams of microglial protein. 
There was no significant difference in protein concentrations among any of the experimental 
groups including those with the highest nitrite values, i.e., p25-35 in combination with IFN-y 
(F= 1.386, df=2,3, P=0.370). However, a ratio of nitrite per milligram of microglial protein 
was significantly increased by IFN-y (1000 U/ml) alone (t=3.974, df=4, P=0.020) or IFN-y 
(100, 500, or 1(X)0 U/ml) in combination with P25-35 (F=4.34, df=4,33, P=0.006). This 
experiment shows that IFN-y significantly induces nitric oxide release from microglial cells 
exposed to P25-35, and does so in a dose dependent manner (Figure 2). Optimum levels of 
nitrite in microglial cultures appear to be at IFN-y concentrations starting at 100 U/ml in 
combination with |325-35. 
The microglial response to p 1-40 was studied with or without co-exposure with INF-y 
to compare it with P25-35. Nitrite was assayed in the culture media of microglial cells grown 
on p 1 -40 for 4 days and exposed to EFN-y (ICX) U/ml) for 3 days starting at post-plating day 1. 
Cellular protein content was also assayed. Microglial release of nitric oxide was expressed as a 
ratio of nitrite per milligrams of microglial protein (Figure 3). Unlike the p25-35 condition, 
the cellular protein assay indicated a significant increase in protein levels in groups of 
microglial cells exposed to pi-40 (t=-6.047, df=4, p=0.0038). However, the nitrite/protein 
ratio also indicated a significant increase in microglial nitric oxide release as compared with the 
control condition (t=-3.727, df=4, p=0.0033). pi-40 co-exposed with IFN-y (100 U/ml) 
elicited an even greater effect. This synergistic effect of pi-40 and IFN-y was significant as 
compared with either pi-40 (t=-4.250, df=4, P=0.0008) or IFN-y alone (t=-7.65I, df=4, 
p=0.0001). 
To examine whether nitrite accumulation in the media was nitric oxide synthase-
specifiic, microglial cells were exposed to N^-Monomethyl-L-Arginine (NMA, 500 nM). a 
guanidino-N-substituted L-arginine analog that acts as a competitive inhibitor of nitric oxide 
synthase The effect of pi-40 on nitrite levels in the microglial supernatant was substantially 
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reduced by the inclusion of NMA in the cultures. Cultures containing NMA were not 
significantly different from the control (t=-0.013, df=4, P=0.98). 
Discussion 
Until recently, very little research has focused on a possible role for glial cells in p-
amyloid-mediated neuronal degeneration in AD. The differences in morphology of diffuse, 
putatively 'early' p-amyloid plaques of AD which lack reactive glia cells, and classic neuritic 
plaques which clearly have reactive glia cells, along with degenerating neurites, favor some 
kind of glial involvement. The present study shows that nriicroglia are induced to release nitric 
oxide by pi-40 alone and by the synergistic action of p25-35 with IFN-y. 
The cellular effects of p-amyloid were studied using synthetic p-amyloid peptides (P25-
35 and pi-40). pi-40 is a large fragment of the 42 amino acid p-amyloid protein found in the 
neuritic plaques, and P25-35 peptide, corresponding to amino acids 25-35 of the full length 
peptide, has been shown to be a neurotoxic portion of p-amyloid28,47 jj^e present smdy 
examined microglial release of nitric oxide by exposing microglia to p25-35 and pi-40 coated 
on to the surface of culture wells. This exposure method differs from that of previous studies. 
Most previous tissue culture studies have sought to determine the effects of p-amyloid by 
solubilizing it or suspending it in culture medium despite the fact that p-amyloid found in the 
AD neuritic plaques is relatively immobile and insoluble. Our alternative method not only 
ensures that most cells are exposed to p-amyloid, but it also prevents any possible physical 
cellular damage by aggregated, mobile p-amyloid. 
The results of this study support the notion that p-amyloid may be responsible for 
activation of microglia in vivo. This assertion is based on both morphological observations 
and assay of nitric oxide relea.se (nitric oxide being a product of an activated macrophage) from 
cultured microglia in response to p-amyloid. Microglial cells are known to undergo a variety of 
morphological transformations in vitro in response to various cytokines (e.g.. IFN-y and 
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colony stimulating factors) and other factors (e.g., LPS)^^'^^. These changes in morphology 
are thought to indicate changes in the function of microglia, based on the correlation between 
enzymatic activity, superoxide anion formation, and proliferation with the various 
morphological forms of cultured microglials, it is suggested that the round ameboid microglia 
seen in culture are the most active form, rod-shaped microglia are the proliferative form, and 
ramified microglia (a branched form not observed in the present study) are resting microglials. 
If these criteria are applied to the present smdy, it would appear that p-amyloid (P25-35 and pi-
40) can cause both proliferation and activation of microglia, since both the ameboid and rod-
shaped forms were present in cultures exposed to p-amyloid. 
To examine whether these morphological transformations induced by p-amyloid and 
IFN-y reflect nitric oxide synthase activity, microglial cells were stained with a marker for 
NADPH-diaphorase whose enzymatic activity is accepted as a histochemical indicator of NOS 
activity"^!. Nitric oxide synthase activity did not exactly correlate with a given morphology of 
microglia. While it was the spherical (active) ameboid cells in the p-amyloid condition that 
usually showed the most nitric oxide synthase activity, ceils with identical morphology in the 
IFN-y condition did not always show increased nitric oxide synthase activity. There were 
subjectively more spherical cells in the p-amyloid condition when IFN-y was added, and it was 
these cells that showed the most nitric oxide synthase activity. These observations would 
suggest that while ER^I-y can activate cells (inducing the spherical ameboid morphology), it is 
the synergistic action of both p-amyloid and EFN-y which consistently induces microglial nitric 
oxide synthase activity. 
Much remains to be learned about the mechanisms involved in the release of nitric 
oxide. In the peritoneal macrophage, IFN-y, but not other cytokines, stimulated the release of 
nitric oxide46. whereas in smooth muscle cells^l and pancreatic macrophages-^ it is 
interleukin-l (IL-1) which mediates such an effect. Activation of cortical microglia! cells with 
IFN-y and LPS induced high levels of nitric oxide, accompanied by a marked reduction in 
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neuronal cell survival^. Therefore, it appears that maximum nitric oxide release from cells of 
the mononuclear phagocytic system (including microglia) depends on the synergistic action of 
a priming agent (e.g. IFN-a/p, IFN-y, TNF-a/p, or IL-ip) and a triggering agent (e.g. 
LPS)6,9,31,51, 
In the present smdy p-amyloid (P25-35 peptide) is used as a triggering agent for nitric 
oxide release from microglia, and it is co-exposed with the priming agents IFN-a/p, IFN-y, 
TNF-a, TNF-p, or IL-ip. While P25-35 alone did not trigger nitric oxide release from 
hippocampal microglia, it did so when microglia were activated with IFN-y (100, 500, and 
1000 U/ml). IFN-y is known to activate microglia, the consequences of which would include 
increased IL-1 and superoxide anion release, and decreased chemotaxis^. In our study, IFN-y 
did significantly induce nitric oxide release from microglia and this effect was greatest in the 
presence of P25-35. It would appear that while IFN-y activates hippocampal microglia, it is the 
synergistic action of DFN-y and P25-35 that results in maximum nitric oxide release. Likewise, 
P25-35 alone does not induce nitric oxide release from microglia unless microglia are first 
activated with a factor such as IFN-y. This is supported by the changes in microglia 
morphology mentioned earlier. The nitric oxide-releasing effect of P25-35 is specific to this 
peptide, as a control peptide (scrambled P25-35) coated onto culture wells in the same manner 
did not elicit nitric oxide release from microglia, even when co-exposed with IFN-y. 
Our morphologic observations of a subjective increase in the appearance of rod-shaped 
microglia in the P25-35 conditions suggest a proliferation of microglial cells. However, cellular 
protein analysis detected no significant differences in microglial protein among any of the 
experimental conditions involving P25-35 and the various cytokines. Therefore, nitric oxide 
release from microglia exposed to P25-35 and IFN-y, expressed as nitrite/mg. protein, must be 
the result of increased nitric oxide synthase activity per microglia cell and can not be accounted 
for simply by an increase in nitric oxide-releasing microglia. 
26 
Microglia exposed to P1-40 responded somewhat differently from those exposed to 
P25-35. First, pi-40 induced a significant nitric oxide release from microglial cells by itself. 
This has been seen in peritoneal macrophages where pi-40, but not P25-35, induced nitric 
oxide release22. Also, unlike p25-35, pi-40 did induce proliferation of microglia, as shown 
previously 1. Protein analysis showed a significant increase in protein content in the pi-40 
condition. However, nitric oxide release was still significant when this proliferation was taken 
into account by calculating nitrite/protein content. This nitric oxide-releasing effect on 
microglia by p 1 -40 was further increased when microglia were co-exposed with IFN-y. 
The enhancing effect of IFN-y on p-amyloid-mediated release of microglial nitric oxide 
suggests a possible role for T-cells at the sites of p-amyloid deposit. IFN-y is produced 
predominantly by activated T-cells ^ 8. In healthy mammals, the CNS contains T-lymphocytes 
in such low concentrations that they are virtually undetectable by immunohistochemical 
methods In AD, T-cells are observed in the brain and are often associated with neuritic 
plaques^^'^^ along with HLA-DR-positive microglial cells and cytokines (IL-1, TGF-
p) 12,13,40 hLA-DR expression is generally considered to signify the immunocompetent 
status of a celP^, and it is involved in the presentation of antigen by activated microglia to T-
cells^'^^. Therefore, a scenario involving microglia and T-cells could conceivably be part of 
the pathogenesis of neurodegeneration following p-amyloid deposition in AD. 
The mechanisms involved in neuritic plaque formation and neuronal degeneration in AD 
are not known. In the rodent, microglial nitric oxide release has been shown to be neurotoxic in 
vitro. This suggests nitric oxide could play a role in human neurodegenerative diseases such as 
AD. However, it must be noted that there are interspecies differences in the production of 
nitrites from macrophages and microglia. For instance, it was shown thai human monocyte-
derived macrophages do not produce detectable levels of nitrite when exposed to concentrations 
of IFN-y plus LPS which would be sufficient to cause nitrite release in the mouse or rat^^. 
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However, human monocyte-derived macrophages infected with Mycobacterium avium and 
exposed to TNF-a were shown to release high levels of nitrite^. In regard to microglia 
specifically, it was shown that human fetal microglia did not produce detectable levels of nitrite 
when stimulated with various cytokines including EFN-y and an unspecified concentration of 
LPS^^. However, a more recent study showed that human fetal and adult microglia did 
produce low, but significant, levels of nitrite upon stimulation with IFN-y and LPS^^ is 
evident from these studies that variations of microglial nitric oxide release between species 
exist, but this may be due in part to differences in the methods employed, i.e., developmental 
stage or age of the species used, microglial isolation procedure and stimulation protocol. 
Therefore, until definitive studies comparing nitrite release from human and rat microglia are 
done, extrapolations from the results of rodent studies must be made with caution but cannot be 
dismissed. Furthermore, a study involving the effects of p-amyloid on human microglia is 
needed to establish whether p-amyloid-induced microglial nitric oxide release has a role in 
Alzheimer's disease. 
The present study demonstrates that pi-40 alone is sufficient to induce microglial 
release of nitric oxide in the rat and that this activity can be enhanced by the synergistic action 
of IFN-y in vitro. It is possible that p-amyloid activation of microglial cells is one mechanism 
responsible for neuronal degeneration in humans, and therefore the possiblity of a glial role in 
P-amyloid-mediated neurotoxicity in AD must be seriously considered. 
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FIGURE 1. Effects of P25-35 co-exposed with IFN-y on the morphology and NADPH-
diaphorase staining of microglia cells in vitro. Control microglia at post-plating day 3 (A^) 
are characterized by a round, flat, ameboid-like morphology. Microglia plated on to P25-35 
substrate and exposed to IFN-y (100 U/ml; C,D) for 60 hours starting at post-plating day I 
were characterized by either a rod-shaped or compact, spherical morphology. Microglia were 
stained for NADPH-diaphorase, as a measure of nitric oxide synthase activity, on post-plating 
day 4 (B,D). There was little or no staining of control microglia (B), whereas |325-35 and 
IFN-y-exposed microglia exhibiting the spherical morphology showed positive staining (D). 
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TABLE 1. Nitrite (a metabolite of nitric oxide) was assayed in supematants from microglia 
exposed to various cytokines, P25-35, or a control peptide. Microglia were exposed to P25-35 
or a control peptide for 72 hours starting on post-plating day 0, and to each cytokine for 60 
hours starting at post-plating day I. Only P25-35 co-exposed with IFN-y (100 U/ml) induced 
significant nitric oxide release from microglia. Values represent the mean ± SEM for triplicate 
experiments. ** = P < 0.02 as compared with IFN-y (100 U/ml) alone. 
Nitrite (|iM/50,000 cells) 
Cytokines Concentration Cytokine Cytokine Cytokine 
(U/ml) alone with control peptide wim P25-35 
Control N/A 0.644±0.166 0.720±0.09 0.64410.166 
IFN-a/p 100 1.613±1.064 1.765±1.04 1.936±1.274 
TNF-a 100 0.587±0.050 0.740±0.15 0.62510.069 
TNF-p 100 0.606±0.119 0.775±0.14 0.58710.050 
IL-ip 
IFN-y 
IFN-y 
100 0.320±0.057 0.568±0.10 0.24010.070 
10 0.72010.424 1.11210.112ns 
100 1.181±0.112 12.86716.020=^=^ 
IFN-y 500 3.092±1.449 22.66817.472=^=^ 
IFN-y 1000 6.556±1.149 5.196±4.90 14.44812.640=^=^ 
ns = not significant compared with IFN-y (10 U/ml) alone. 
** p<0.001 compared with IFN-y (100,500 or 1000 U/ml) 
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FIGURE 2. Dose response relationship for the effect of IFN-y on nitrite release from microglia 
with or without co-exposure to P25-35. Microglia were exposed to P25-35 for 72 hours 
starting on post-plating day 0, and to IFN-y for 60 hours starting at post-plating day 1. IFN-y 
(1000 U/ml) and P25-35 co-exposed with IFN-y (100. 5(X), or 1000 U/ml) induced significant 
nitric oxide release from microglia. Values represent the mean ± SEM for triplicate 
experiments. 
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FIGURE 3. Effect of pi-40 and IFN-y on nitrite release from microglia. Microglia were 
exposed to pi-40 for 72 hours starting on post-plating day 0, and to IFN-y (100 U/ml) for 60 
hours starting at post-plating day I. Microglia were exposed to N^-Monomethyl-L-Arginine 
(NMA) for 72 hours starting at post-plating day 0. pi-40 induced significant nitric oxide 
release from microglia. The effect of pi-40 was enhanced by co-exposure with IFN-y and 
blocked by exposure to NMA. Values represent the mean ± SEM for triplicate experiments. 
CHAPTER 3: INTEGRIN MAC-1 AND p-AMYLOID IN MICROGLIAL 
RELEASE OF NITRIC OXIDE 
A paper to be submitted to Brain Research 
Jeffrey L. Goodwin, Marcus E. Kehrli, Jr., Etsuro Uemura 
Summary 
The p-amyloid protein associated with Alzheimer's Disease (AD) has been well 
characterized biochemically; however, its primary biological function and mode of action in AD 
has not been determined. We have shown previously that p-amyloid (B25-35), in combination 
with Interferon gamma (IFN-y), can induce nitric oxide release from cultured hippocampal 
microglial cells. In the present study, binding of p-amyloid with the leukocyte integrin Mac-1, a 
cell surface receptor on microglia, was studied by observing (1) inhibition of p-amyloid (P25-
35)-mediated release of nitric oxide from cultured microglial cells following exposure to 
monoclonal antibodies against Mac-1 (anti-CD 18 and anti-CD 1 lb) and (2) competitive binding 
of fluorochrome-labeled p25-35 with anti-CDlS or anti-CDllb using fluorescent flow 
cytometry. Wt.3 (anti-CDI8 antibody) and 0X42 (anti-CDllb antibody) were as effective as 
opsonized zymosan at inducing the release of nitric oxide from microglia. Furthermore, Wt.3 
and 0X42 acted synergistically to induce maximum nitric oxide release. An interaction between 
p-amyloid and CD 18 of Mac-1 was evidenced by the suppressive action of P25-35 on Wt.3-
mediated release of nitric oxide and the synergistic action between 0X42 and P25-35 in 
inducing nitric oxide release from microglia. The tissue culture study was supponed by 
competitive binding assays of fluorochrome-labeled p25-35 and Mac-1 antibodies (Wt.3 or 
0X42). The majority of microglial cells (71%) did bind biotinylated P-amyloid in the presence 
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of Cytochalasin B, suggesting tliat p-amyloid binding to microglia is a receptor-mediated event. 
Furthermore, pre-exposure to Wt.3, but not 0X42, significantly decreased binding of 
biotinyiated P25-35 to microglia. These findings suggest that CT) 18 of Mac-1 may play a role in 
P-amyloid-mediated release of nitric oxide. 
Introduction 
While the p-amyloid protein associated with Alzheimer's disease (AD) has been well 
characterized biochemically, its primary biological ftinction and mode of action in AD has not 
been determined, p-amyloid occupies the core of neuritic plaques which are made of 
degenerative neurites. Microglial cells, in their reactive form, are found closely associated with 
matured neuritic plaques [22]; however, very little information has been available on the effects 
of the p-amyloid present in the neuritic plaques on microglial cells. 
In the rodent, microglial cells release the free radical nitric oxide [7,8,24,42]. This may 
have significance in the pathogenesis of AD given that nitric oxide release from microglia is 
accompanied by a marked reduction in neuronal cell survival in vitro [12]. The inducible nitric 
oxide synthase (iNOS) found in microglia is calcium- and calmodulin-independent and must be 
induced by agents such as bacterial cell wall lipopolysaccharide (LPS) or IFN-y 
[12,18.38,42]. We have shown that cultured microglial cells respond to IFN-y when co-
stimulated with either pi-40 or P25-35 to release nitric oxide, while only pi-40 induces 
significant nitric oxide release from microglial cells by itself [19]. These findings were also 
demonstrated, in part, by Meda, et al. [26] who reported a synergistic effect between P25-35 
and IFN-y in triggering nitric oxide and tumor-necrosis factor-a (TNF-a) release from 
microglia. Similarly, it was shown that rodent peritoneal macrophages without priming with 
IFN-y. are activiated by pi-40 but not by p25-35 [23]. The results of these studies support the 
notion that p-amyloid may be responsible for activation of microglia and subsequent nitric 
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oxide release in vivo. At present, the triggering mechanisms involved in microglial stimulation 
for release of nitric oxide have not been documented. 
Our hypothesis is that a microglial receptor through which p-amyloid might trigger nitric 
oxide release is the leukocyte integrin Mac-1. The Mac-1 receptor is a likely choice given that, 
when bound by appropriate ligands in the presence of a co-stimulatory factor such as IFN-y, 
Mac-1 activates macrophages and neutrophils to produce reactive mediators including reactive 
oxygen intermediates and nitric oxide [13,14,16,27,31]. Coincidentally, 325-35 in 
combination with IFN-y stimulates iNOS activity and the release of nitric oxide from microglia 
[19]. Mac-1 belongs to a family of adhesion molecules composed of a heterodimer between an 
a- and p-subunit found exclusively on leukocytes or cells of this lineage. Each of these 
adhesion molecule shares an identical p subunit (CD 18) and is distinguished by its a subunit 
designated CDIIa, CDl lb, and CDl Ic for LFA-1, Mac-1, and pi50,95a, respectively [21]. 
Microglial cells express Mac-1 and in AD, Mac-1 expression is upregulated in reactive 
microglial cells associated with the neuritic plaques [1,30]. RecenUy it was reported that 
antibody to CD 18 was found to stimulate nitric oxide production and inducible nitric oxide 
synthase mRNA expression in alveolar macrophages [29]. In the present studies, we 
investigated a potential role for CDl lb and CD 18 of Mac-1 in p-amyloid-mediated release of 
niuic oxide from cultured hippocampal microglia. 
Materials and methods 
Synthesis and biotinyiation of p-amyloid peptide 
P-amyloid (P25-35) was synthesized and purified by the University of Iowa Protein 
Structure Facility (Iowa city. lA). P25-35 was dissolved in sterile tissue culmre water (Sigma) 
or 0.1 M PBS (for Mac-1 binding studies) in a stock concentration of 1 mg/ml (pH 7.2) and 
aliquots were stored at -20 °C. P25-35 was biotinylated according to a protocol obtained from 
Vector Laboratories. Briefly. P25-35 was dissolved in 1(X) mM HEPES buffer. pH 8.5. at a 
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concentration of 2 mg/ml, then 400 nl biotinamidocaproic acid 3-sulfo-N-hydroxysuccinimide 
ester (Sigma) was added, and the solution was incubated at room temperamre for 2 hours. The 
biotinylated P25-35 was dialyzed against 2 changes of O.I M PBS, pH 7.2, overnight to 
remove unreacted biotin ester, adjusted to a concentration of I mg/ml and stored at 4 °C until 
use. 
Microglial culture 
Microglia were obtained from the hippocampi of 3-5 day old rat pups (Harlan Sprague-
Dawley, Indianapolis, IN). The hippocampi were dissected and the cells separated by 
trypsinization and mechanical dissociation. The cell suspension was diluted to 5 ml with MEM 
culture media supplemented with 10% FBS, 40 mM glucose, 2 mM Il-glutamine, I mM 
pyruvate, 14 mM NaHCOs, 100 lU/ml penicillin, and 100 ng/ml streptomycin. The cell 
suspension was added to 25 cm2 tissue culture flasks and incubated at 37 °C in a humidified 
5% CO2 atmosphere. After 12-14 days in culture, microglia were harvested from the mixed 
glial culture by gently shaking the flasks and pouring off the suspended microglia. The 
microglia were either used immediately for flow cytometry, or replated into 24-well Coming 
Cell well plates for the p2 integrin blocking smdies. Culture purity was established with 
immunocytochemistry by observing positive staining with Mac-1 antibody and negative 
staining with anti-galactocerebroside c for oligodendrocytes and anti-glial fibrillary acidic 
protein for astrocytes. 
Nitric oxide blocking studies 
The relationship between Mac-1 and p-amyloid-mediated nitric oxide release was smdied 
by observing the effects of Wt.3 (anti-CD18 monoclonal antibody; Pharmingen) and 0X42 
(anti-CDlib monoclonal antibody; Pharmingen) on nitric oxide release from microglia. The 
initial study was to examine the microglial release of nitric oxide under the various conu-ol and 
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B25-35 conditions. Harvested microglia were pelleted, resuspended in culture media containing 
B25-35 (50 ^g/500 jil media) at a concentration of 100,000 cells/ml, and plated onto 24-welI 
tissue culture. On post-plating day 1, the media was replaced with fresh media (500 (il) alone, 
or media (500 |il) containing opsonized zymosan (200 ng/ml) or an isotype control antibody 
(50 |ig/ml). On post-plating day 4, the culture supematants were collected for assay of nitric 
oxide, and the cells were resuspended in EBSS (1 ml/well) for cellular protein determination. 
To determine if there was a competitive effect between p-amyloid and Wt.3 or OX42 in 
mediating nitric oxide release, harvested microglia were pelleted, resuspended in 0.1 M PBS 
(100 nl), pH 7.2, containing 625-35 (50 ng/5(X) |xl media), and plated onto 24-well tissue 
culture plates. Opsonized zymosan was used as a positive control. On post-plating day I, 
fresh media (500 til) alone, or media containing and 5 ng/ml Wt.3,0X42 or the isotype control 
antobody was added to the culture wells. On post-plating day 4, the culture supematants were 
collected for assay of nitric oxide and cellular protein. Each experiment was repeated 3 times 
using quadruplicate wells. 
Measurement of nitrite 
Nitric oxide production was determined indirectly through the assay of nitrite (NO2), a 
metabolite of nitric oxide, based on the Griess reaction [23]. Briefly, a sample of the 
supernatant from each microglia cell condition (500 |il) was mixed with an equal volume of 
Griess reagent (a mixture of 0.1% N-(I-naphthyl)ethylenediamine dihydrochloride and 1% 
sulfanilamide in 2% phosphoric acid), and its absorbance at 550 nm was read on a Roy 
Spectronic 601 spectrophotometer. Nitrite in cell-free medium was determined in each 
experiment and subtracted from the value obtained with cells. Nitrite concentrations were 
calculated from the absorbency values by plotting them on a standard curve established using 
sodium nitrite at known concentrations ranging from 1 to 125 nM. 
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Cellular protein assay 
In the Mac-1 blocking studies, cellular protein concentrations in each culture well were 
determined using the Bio-Rad Protein Assay (microassay procedure). Protein concentrations 
were calculated from the absorbency values by plotting them on a standard curve using the 
bovine gamma globulin standard at concentrations ranging from 1 to 25 |ig/ml. 
Flow cytometry studies 
Interactions of p-amyloid with P2 integrins were studied by competitive binding analyses 
using various combinations of unlabeled and fluorochrome labeled p-amyloid and monoclonal 
antibodies against the a subunit of Mac 1 (CDIlb) and the common p subunit (CD 18) of the P2 
integrins (Table 1). Harvested microglia were pelleted and resuspended in 1 ml of 0.1 M PBS 
without Ca^* and Mg^* at a concentration of 1 x 10' cells/ml. To verify cell surface receptor-
specific p-amyloid binding to the cells, microglia were pelleted, resuspended in 100 jd 
biotinylated P25-35 (I mg/ml, pH 7.2) and incubated for 15 minutes in the presence or absence 
of cytochalasin B (10 |ig/ml; Sigma), which decreases any microtubule-associated 
internalization of p25-35. Cells were washed once in PBS, resuspended in 100 ni PBS 
containing 10 nl streptavidin (R-phycoerythrin conjugate; Sigma) and incubated for 15 minutes 
at room temperature. Cells were washed twice in PBS then resuspended in 500 iil sheath fluid 
(Isoton U; Coulter) for flow cytometric analysis. 
To see if antibodies directed against the P2 integrins could competitively inhibit the binding 
of biotinylated p-amyloid to microglia, microglia were pretreated with either Wt.3 or 0X42. 
Harvested microglia were pelleted and resuspended in 1 ml PBS at 1 x 10' cells/ml. Cells were 
centrifuged, resuspended in 100 M.1 PBS containing 10 nl (50 |ig/ml stock concentration) Wt.3 
or 0X42 and incubated for 15 minutes at room temperature. Cells were washed once in PBS 
then incubated with biotinylated P25-35 and prepared for fluorescence analysis as described 
above. 
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Immunofluorescent analysis of the flourochrome labeled microglia was performed in a 
fluorescence-activated cell sorter fluorometer (FACScan; Becton, Dickinson & Co). Values 
were obtained for specific fluorescence intensity (mean fluorescence channel of histogram) and 
percentage of cells positively labelled on at least 3 separate occasions for each condition using 
Cell Quest® software. 
Statistical analysis 
All data were analyzed for group differences by analysis of variance (ANOVA) and 
significant effects were further analyzed by the Tukey's B posthoc procedure. 
Results 
The effect of Wt. 3 and 0X42 on nitric oxide release from microglia 
Antibodies specific for antigen-binding sites on Mac-1 are known to elicit a number of 
cell responses including respiratory burst activity. Therefore, before observing the effects of 
these antibodies on p-amyloid mediated release of nitric oxide from microglia, it was necessary 
to determine what if any effect Wt.3 or 0X42 had on nitric oxide release from microglia. In 
this experiment, nitric oxide levels were measured in the culture media of microglia exposed to 
Wt.3 or OX42. We first examined the microglial release of nitric oxide under the various 
control (opsonized zymosan, mouse IgG) and p-amyloid (P25-35) conditions (Fig. 1). 
Opsonized zymosan, known to induce respiratory burst activity in phagocytic cells by binding 
to Mac-1, was used as a positive control. Opsonized zymosan induced a significant increase in 
microglial release of nitric oxide (F=II.8, df=6, 21, p=0.0001). There was no difference in 
nitric oxide levels induced by p-amyloid (P25-35) or p-amyloid supplemented with isotype 
antibody control. Since isotype antibody did not induce significant levels of nitric oxide, it was 
used as the negative control antibody for the study of Wt.3 and OX42 (Fig. 2). Microglial 
release of nitric oxide was significantly increased by Wt.3, OX42, and a combination of both 
antibodies (F=47.4, df= 3, 48, p=0.0001). Both Wt.3 and 0X42 are equally effective as an 
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inducer of nitric oxide; furthermore, a combination of Wt.3 and 0X42 acted synergistically to 
induce significantly more nitric oxide release over Wt. 3 (t=-2.6, df=6, p=0.012) or 0X42 
alone (t=-3.0, df=6, p=0.005). 
The effect of P25-35 on Wt.3- and OX42-induced nitrite release from 
microglia 
Since both Wt.3 and 0X42 induced nitrite release from cultured microglia, microglial cells 
were first exposed to P25-35, then they were exposed to either Wt.3, 0X42, or a combination 
of both antibodies. P25-35 alone did not induce significant nitrite release from microglia. If p-
amyloid acts at one of the antibody binding sites, it should inhibit the nitric oxide release in 
response to that antibody by blocking antibody-mediated activation of Mac-1. Fig. 2 shows 
the effect of Wt.3, 0X42 and a combination of both antibodies on p-amyloid-mediated release 
of nitric oxide. Nitric oxide release mediated by Wt.3 was the only condition significantly 
reduced by preexposing cells to p25-35 (t=8.40, df=6, p=0.0001). In contrast, P25-35 
significantly increased nitric oxide release by 0X42 (t=-3.59, df=6, p=0.002). A further 
increase in nitric oxide release was induced by P25-35 with a combination of Wt.3 and 0X42 
(t=-5.6, df=6, p=0.001). As a result, there was no difference in levels of nitric oxide induced 
by a combination of two antibodies (Wt.3 and 0X42) with or without p25-35. There was no 
significant difference in cellular protein content among any of the experimental groups. 
P25-35 binding to microglia 
The first step in identifying a microglial p-amyloid receptor was to demonstrate that p-
amyloid binds to microglia in a cell-surface specific fashion. Cultured microglia were incubated 
with biotinylated P25-35 in the presence or absence of cytochalasin B, and analyzed by a flow 
cytometer for the mean percent positive labeling (Fig. 3) and fluorescence intensity (MFI) of 
microglia with biotinylated P25-35. 
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The MFI of microglia exposed to biotinylated P25-35 was significantly higher than the 
biotin control (t=-3.0, df=4, p=0.017; data not shown) and over 70% of cultured microglia 
bound P25-35 (t=-11.19, df=4, p=0.0001). Cytochalasin B did not reduce either the MFI of 
microglia binding to biotinylated P25-35 or percent of microglia which bound biotinylated p25-
35. The flow cytometry data suggest ^25-35 binding to microglia and no internalization of p25-
35 by microglia. To demonstrate the presence of specific microglial receptors with an affinity 
for p-amyloid, the binding of biotinylated P25-35 was compared with that of a biotinylated 
scrambled control peptide. The percentage of cells positively labeled with biotinylated 
scrambled peptide was not significantly different from control cells. 
Competitive binding between biotinylated p25-35 and Wt.3 and 0X42 
Once it was established that p-amyloid bound to cultured microglia, the next step was to 
confirm our tissue culture experiments which suggested that p-amyloid mediates nitric oxide 
release from microglia by binding to Q)18 of the Mac-1 integrin. If p-amyloid binds to 
microglial Mac-1 at either the CD 18 or CD I lb site, as we hypothesized, pre-incubation with 
the anti-CD 18 or anti-CD lib monoclonal antibody should competitively inhibit binding of 
biotinylated P25-35 to cultured microglial cells. To test this, mean fluorescence intensity (MFI) 
and percent positive labeling of microglia with biotinylated P25-35 were analyzed in microglial 
cells incubated with biotinylated 625-35 with and without pre-exposure to Wt.3 or 0x42. 
There were significant decreases in MH (F=8.73. df=2,6, p=0.017) and percent positive 
labeling (F=6.11, df=2,6. p=0.036) of microglial cells preexposed to Wt.3 as compared with 
the control group antibody (Fig. 4). No such effect was observed in microglial cells 
preexposed to 0X42. 
Discussion 
Microglial cell interactions with p-amyloid were studied using a synthetic P25-35 peptide. 
P25-35 peptide corresponds to amino acid 25-35 of the 42 amino acid p-amyloid protein found 
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in the neuritic plaques and has been shown to be a neurotoxic portion of p-amyloid [25, 40]. 
Our previous study demonstrated that P25-35 stimulates nitric oxide release from microglia 
only when coexposed with DFN-y [19]. In search of a cellular binding site through which |3-
amyloid acts to trigger nitric oxide release from microglia, we investigated the leukocyte 
integrin Mac-1. The respiratory burst response, which includes nitric oxide release, of 
macrophages and granulocytes is mediated through Mac-1. A maximum response of these cells 
requires the synergistic action of IFN-y and a second ligand such as LPS [13,16,27,31]. 
Coincidentaly, iNOS activity and the release of nitric oxide from microglia is stimulated by the 
synergistic action of IFN-y and P25-35 [19]. Given these observations and that Mac-1 can 
mediate a co-stimulatory signal in a variety of cells, Mac-1 is a likely candidate through which 
P-amyloid acts to stimulate nitric oxide release from microglia. 
Mac-1 is a leukocyte integrin expressed primarily on myeloid and natural killer cells. It is 
responsible, in part, for myeloid cell adhesion to endothelium, neutrophil homotypic adhesion 
and chemotaxis, and phagocytosis of opsonized particles. It does this by binding to several cell 
surface and soluble ligands including iC3b, ICAM, fibrinogen, factor X, filamentous 
hemagglutinin, lipophosphoglycan, and LPS [2,3,4,6,34,36,37]. Mac-1 consists of a QDIlb 
a chain noncovalentiy associated with a CD 18 p chain. The binding sites for most of the 
aforementioned ligands, except for a lectin-like binding site, have been mapped to the I region 
of the a-chain [II]. The extracellular N-terminal domains of the a and p subunits combine to 
form a ligand-binding head which is ultimately connected to two cytoplasmic domains. These 
cytoplasmic domains are believed to interact with cytoskeletal proteins or other cytoplasmic 
components and enable integrins to act as signaling receptors [21]. An important feature of 
many integrins is that they undergo activation which is accompanied by a conformational 
change that is required for various ligand-binding activities. Activation of the p, integrins can 
be accomplished by solid phase reactants (e.g. fibrinogen), monoclonal antibodies, and various 
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inflammatory mediators such as tumor necrosis factor, C5a, platelet activating factor, or IFN-y 
[21]. 
To demonstrate that p-amyloid interacts with Mac-1 to induce nitric oxide release from 
microglia we performed two studies: 1) the effects of anti-Mac-1 monoclonal antibodies (Wt.3 
and 0X42) on p-amyloid (p25-35)-mediated release of nitric oxide from cultured microglial 
cells and 2) competitive binding of fluorochrome-labeled P25-35 with CD 18 or CDl lb by 
fluorescent flow cytometry. The first step was to determine whether microglial nitric oxide 
release is mediated through Mac-1. Since it has been shown that monoclonal antibodies can act 
as natural ligands for phagocyte receptors associated with functional activation [20], we 
examined the effects of Wt.3 and 0X42 alone on microglial release of nitric oxide. Both Wt.3 
and 0X42 were as effective as opsonized zymosan in inducing the microglial release of nitric 
oxide. Furthermore, Wt.3 and 0X42 acted synergistically to induce maximum nitric oxide 
release. Although little is known about the mode of action of Mac-1 in response to stimulatory 
signals, it has been shown in monocytes that CD 18 does not induce respiratory burst activity 
without the help of CD lib [17]. Furthermore, ligand binding to CDl lb not only increases the 
binding of ligands to CD 18, but it also induces an optimal respiratory burst and release of free 
radicals from macrophages by legation of CD18 [14,17]. Our data suggest that ligand binding 
to CD 18 or CDl lb alone can induce the release of nitric oxide in microglial cells, however, it is 
the combined action of both CD 18 and CDl lb that optimizes the microglial response. 
Interaction of p-amyloid with the microglial Mac-1 was shown by the suppressive action 
of P25-35 on Wt.3-mediated release of nitric oxide. P25-35 significantly reduced nitric oxide 
release from microglia exposed to Wt.3, but not 0X42. This suggests that p-amyloid binds to a 
site on CD 18 either directly at the Wt.3 binding, or close enough to the Wt.3 binding site to 
interfere with the binding of Wt.3 by other means, e.g., steric hindrance. Since Mac-1 is 
capable of undergoing a conformational change upon activation by various stimuli [21], the 
suppressive action of P25-35 on Wt.3-mediated release of nitric oxide could also be due to a 
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conformational change of Mac-1 by p25-35 and subsequent disruption of Wt.3 binding at its 
site on CD 18. A role for CD lib in nitric oxide release was also suggested by our study 
showing a significant increase in nitric oxide release by P25-35 and 0X42. 
Supportive data on receptor-mediated binding of p-amyloid by microglia was obtained by 
competitive binding assays of fluorochrome-labeled p25-35. The majority of microglial cells 
(71%) bound biotinylated P25-35. This positive binding could not be explained by 
microtubule-associated internalization of P25-35 as the binding was not affected by 
cytochalasin B, and binding was relatively specific as binding to the control peptide was not 
different from the biotin control condition. Our hypothesis that p-amyloid is a ligand for Mac-1 
was supported by competitive binding studies of p-amyloid and Mac-1-specific monoclonal 
antibodies. Pretreatment of microglia with Wt.3, but not with 0X42, significantly reduced 
binding of biotinylated P25-35. However, the effect of Wt.3 was not complete. 
There could be a number of explanations for the incomplete blocking effect of Wt.3 on 
microglial binding of 625-35. Mac-1 is known to have numerous binding sites; therefore, p25-
35 could be binding to sites other than those blocked by Wt.3. Another explanation is that 
while Wt.3 is blocking one potential binding site on microglia for P25-35, there are other 
binding sites available on microglia which will bind to P25-35. Two recent reports suggest that 
this might be the case. Yan et al. [39] reported that p-amyloid binds with a microglia-surface 
receptor called RAGE (receptor for advanced glycation end products) and promotes induction 
of oxidative stress in microglia. An unrelated cell-surface receptor, class A SR (scavenger 
receptor), was also shown by El Khoury et al. [15] to interact with p-amyloid, leading to 
secretion of reacdve oxygen species and cell immobilization. However, a signal u^ansduction 
pathway through which RAGE or SR can trigger the producuon of reactive mediators including 
reactive oxygen intermediates and nitric oxide has not been identified. It is possible that RAGE 
and SR act to promote adhesion to p-amyloid and Mac-1 mediates release of reactive mediators. 
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Our study on rodent microglial cells assumes that nitric oxide could play a role in human 
neurodegenerative disease such as AD; however, studies from human microglial ceils are not 
consistent in regard to nitric oxide release in vitro. It was shown that human fetal microglia did 
not produce detectable levels of nitric oxide when stimulated with various cytokines including 
IFN-y and an unspecified concentration of LPS [24], However, two more recent studies 
showed that human fetal and adult microglia produce low, but significant, levels of nitric oxide 
upon stimulation with IFN-y or TNF-a and LPS [29,10]. In this respect, the presence of 
reactive microglia in neuritic plaques can not be ignored considering their upregulation of Mac-
1 and its subunit CD 18 in AD [1,30]. Until definitive studies comparing nitric oxide release 
from human and rat microglia are done, extrapolations from the results of studies on rodent 
must be made with caution but cannot be dismissed. 
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Table I. List of reagents used for tissue culture and flow-cytometric analysis of p-amyloid 
binding to microglial cells. 
Reagaits used Unlabeled PE<onjugated Suppliers 
anti-rat CD18 mAb Wt.3agG,) Pharmingen 
anti-rat CDllb mAb OX42agG:,) Pharmingen 
Isotype control Unrelated mouse IgG Caltag 
b-amyloid (25-35) b25-35 Biotinylated b25-35 Univ. of Iowa 
Scrambled peptide Biotinylated peptide Univ. of Iowa 
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150 
_c 
Control Zymosan Control P25-35 P25-35/ 
antibody Control antibody 
Fig. 1. The effects of p25-35, opsonized zymosan, and isotype control antibody on nitric oxide 
release from cultured microglial cells. Cell were exposed to each factor for 72 hrs starting at 
post-plating day 0. Opsinized zymosan induced significant release of nitric oxide. Each bar 
represents mean values ± SEM for nitrite/mg protein for triplicate experiments. 
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I B25-35/Antibody u 200 
= 100 
Control CD18 CDllb 
Antibodies 
CD18/CDIlb 
Fig. 2. The effects of Wt.3 (anti-CD 18 antibody) and/or 0X42 (anti-CD 1 lb antibody) on nitric 
oxide release from cultured microglial cells. Microglial cells were exposed to P25-35 for 24 hrs 
before exposing to Wt.3 and/or 0X42. Nitrite levels were analyzed at post-plating day 4. p25-
35 alone did not stimulate microglial cells to release nitric oxide. Wt.3 and 0X42 each induced 
significant nitric oxide release from culmred microglia, but maximum nitric oxide release was 
induced by the combination of Wt.3 and OX42. Nitric oxide release mediated by Wt.3 was 
significantly reduced by coexposing cells to P25-35. In contrast, 325-35 significantly increased 
nitric oxide release by 0X42 and a combination of Wt.3 and 0x42. Each bar represents mean 
values ± SEM for nitrite/mg protein for triplicate experiments. 
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Biotin-
P25-35 
Control 
peptide 
Biotin-
P25-35/Cyb 
Biotin 
Control 
Control 
Fig. 3. Percent positive labeling of microglia exposed to biotinylated p25-25 for 15 minutes 
followed by labeling with streptavidin PE. Biotinylated p-amyloid-exposed cells showed a 
significant increase in % positive labeling as compared to the biotin control suggesting binding 
of p-amyloid to the cells. Binding of biotinylated p-amyloid was not significandy reduced 
when microglia were treated with cytochalasin B (CyB) before and during exposure to P-
amyloid. Values represent % positive cells (gated population) ± SEM for triplicate experiments. 
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Fig. 4. Mean fluorescence intensity (MFI) and percent positive labeling of microglia exposed to 
biotinylated (325-35 with and without preexposure to Wt.3 (anti-CD 18 antibody) or 0X42 
(anti-CDlib antibody). Binding of biotinylated p-amyloid by microglia was significantly 
reduced by Wt.3. but not by 0X42. Values represent the MFI or % positive cells (gated 
population) ± SEM for triplicate experiments. 
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CHAPTER 4. GENERAL CONCLUSIONS 
Summary and Discussion 
The research in this dissertation was directed at an examination of the effect of p-
amyloid on nitric oxide release from cultured microglia and a characterization of a mechanism 
by which p-amyloid might act to exert such an effect, i.e. via ligation of the Mac-1 receptor. 
The extent to which p-amyloid affects nitric oxide release from microglia was assessed in 
microglia exposed to two p-amyloid protein fragments (p25-35 and pi-40) alone and in 
combination with the co-stimulatory factors IFN-a/p, IL-ip, TNF-a, TNF-P , and IFN-y. The 
interaction of P-amyloid (P25-35) and the microglial P2 integrin receptor, Mac-1 was smdied by 
quantifying the suppressive effects of anti-Mac-1 monoclonal antibodies (mAbs) on p-amyloid-
mediated release of microglial nitric oxide and assaying competitive binding of biotinylated 
P25-35 and anti-Mac-1 mAbs to microglial cells by inmiunofluorescent flow cytometry. Both 
sets of experiments generated positive and very interesting results. 
In the first paper, microglial release of nitric oxide in response to p-amyloid was 
examined by exposing microglia to p25-35 and pi-40 coated on to the surface of culmre wells. 
Assessment of microglial release of nitric oxide was based on the colorimetric assay for nitrite 
in the culture medium and histochemistry for nitric oxide synthase. Of the cytokines tested, 
only IFN-Y (1000 U/ml) induced nitric oxide release from microglia. P25-35 did not stimulate 
nitric oxide release by itself, but it did induce nitric oxide release when co-exposed with IFN-y 
(100, 500, 10(X) U/ml). In contrast, pi-40 did induce microglial release of nitric oxide by 
itself, and this effect was enhanced significantiy by co-exposure with IFN-y (100 U/ml). The 
results demonstrate that microglia are induced to release nitric oxide by pi-40 alone and by the 
synergistic action of P25-35 with IFN-y. Almost identical findings have now been 
demonstrated, in part, by Meda, et.al.® who reported a synergistic effect between P25-35 and 
IFN-y in triggering not only nitric oxide release, but tumor-necrosis factor-a (TNF-a) release 
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as well, from microglia. The morphological transformations induced by p-amyloid in our 
experiments (which have been described previously') and the increase in nitric oxide synthase 
activity, as well as nitric oxide release, induced by p-amyloid and IFN-y as shown by our lab 
and the work by others, suggest that p-amyloid is an activator of microglia and may be 
responsible for activation of microglia with subsequent neuronal cell injury and degeneration in 
vivo. In the rodent, microglial nitric oxide release has been shown to be neurotoxic in vitro. 
The current findings support the view that oxidative damage may contribute to the process of 
neuronal degeneration that occurs in AD. It must be noted, as reviewed in the first paper, that 
there are interspecies differences in the production of nitrites from macrophages and microglia. 
Unfortunately, without comparable in vivo studies in humans, the assertion that microglial 
release of nitric oxide in response to p-amyloid plays a role in the pathogenesis of AD can be 
nothing more than speculation. 
In search of a cellular binding site through which p-amyloid acts to trigger nitric oxide 
release from microglia, we investigated the leukocyte integrin Mac-1. In the second paper, the 
binding of p-amyioid with Mac-1, a cell surface receptor on microglia which has been 
histochemically shown to be upregulated in AD brains^, was studied by observing (1) P-
amyloid (p25-35)-mediated release of nitric oxide from cultured microglial cells following 
exposure to monoclonal antibodies against Mac-1 (anti-CD18 and anti-CDllb) and (2) 
competitive binding by microglia of fluorochrome-labeled P25-35 and anti-CD 18 or anti-
CD! lb by using fluorescent flow cytometry. Not suprisingly, Wt.3 (anti-CD 18 antibody) and 
0X42 (anti-CDllb antibody) proved to be as effective as our positive control, opsonized 
zymosan, at inducing the release of niuic oxide from microglia. This is not the first report 
demonstrating monoclonal antibody activation of adhesion molecules^. Furthermore, Wt.3 and 
0X42 acted synergistically to induce maximum nitric oxide release. The results of this study 
demonstrate that Mac-1 mediates nitric oxide release in microglia. This is the first report which 
shows a connection between microglial Mac-1 and nitric oxide release. 
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An interaction between p-amyloid and CD 18 of Mac-1 was evidenced, somewhat 
unconventionally, by the suppressive action of P25-35 on Wt.3-mediated release of nitric oxide 
and the synergistic action between 0X42 and P25-35 in inducing nitric oxide release from 
microglia. The tissue culture studies were supported by a competitive binding assay of 
fluorochrome-Iabeled P25-35 and Mac-1 antibodies (Wt.3 or 0X42). Pre-exposure to Wt.3, 
but not 0X42, significantly decreased binding of biotinylated P25-35 to microglia. Taken 
together, the results of these studies suggest that Wt.3 and 325-35 share a common site of 
action on the p chain (CD 18) of Mac-1. The flow cytometry study revealed that the majority of 
microglial cells (71%) did bind biotinylated p-amyloid in the presence of Cytochalasin B. and 
this binding was upregulated by IFN-y (lOOU/ml), all of which suggests that p-amyloid 
binding to microglia is a receptor-mediated event. The tissue culture studies suggest that p-
amyloid binds to Mac-1, however the incomplete blocking effect of Wt.3 on microglial binding 
of P25-35 raises some doubt as to the validity of this conclusion. 
Two recent reports which suggest that there are other binding sites available that will bind 
to P25-35 could explain the discrepancies in our results. As reviewed in the second paper, Yan 
et al.® reported that p-amyloid binds with a microglia-surface receptor called RAGE (receptor 
for advanced glycation end products). An unrelated cell-surface receptor, class A SR 
(scavenger receptor), was also shown by El Khoury et al." to interact with p-amyloid. leading 
to secretion of reactive oxygen species and cell immobilization. These smdies suggest that 
RAGE and SR are involved in signaling microglia to accumulate at sites of p-amyloid 
deposition. They provide convincing evidence that microglia adhere strongly to p-amyloid 
fibrils which can result in microglial activation. However, a signal transduction pathway 
through which RAGE or SR can trigger the production of reactive mediators including reactive 
oxygen intermediates and nitric oxide has not been identified. It is possible that receptors such 
as RAGE and SR act in concert with Mac-1 which results in the pathological changes seen in 
AD. Perhaps p-amyloid in the plaques arrests cell migration via RAGE or SR which pjermits 
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microglia to undergo the sustained activation necessary to induce neurodegeneration via nitric 
oxide toxicity. 
The hypothesis inuroduced in this dissertation, that the neurodegeneration in AD is the 
result of nitric oxide release from microglia in response to p-amyloid binding to microglial Mac-
l, is not directed at the etiology, or first cause, of AD, but rather to a mechanism that may be 
involved in p-amyloid-mediated neurotoxicity. The findings reported here support the current 
'amyloid theory' of AD by suggesting a route by which P-amyloid promotes 
neurodegeneration, in this case via microglial release of nitric oxide. If microglial nitric oxide 
release is proven to play a crucial role in AD, understanding the way in which p-amyloid affects 
microglial release of nitric oxide should be critical for studying the role of microglial cells in the 
pathogenesis of neuronal degeneration in AD. Subsequently, any microglial receptor known to 
bind to p-amyloid, i.e., RAGE, SR or Mac-1, may be possible targets for the development of 
drugs designed to reduce the chronic inflammatory component and neuronal injury associated 
with AD. 
Recommendations for Future Research 
We have shown that p-amyloid in combination with IFN-y induces the release of nitric 
oxide from microglia via a Mac-1-mediated cell signaling pathway in vitro. It is important that 
we take our in vitro experiments one step further and attempt to induce neuronal toxicity in the 
culture dish via p-amyloid-mediated nitric oxide release from microglia. Inducing neuronal 
death by exposing neurons to microglia stimulated by p-amyloid and IFN-y in vitro would 
further support a role for microglia in the pathogenesis of neurodegeneration in AD. The next 
logical step would be to reproduce these experiments in an in vivo model when an animal 
model becomes available. Progress towards an understanding of the pathogenic mechanisms at 
work in AD and in development and testing of therapies based on these mechanisms would be 
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helped by the availability of a convenient animal model. Two recent reports indicate that it may 
indeed be possible to mimic, in transgenic mice, significant aspects of the pathology in AD^ '*. 
Unfortunately, neither mouse model displays both major aspects of AD neuropathology, i.e. 
plaques and tangles. However, mice in which some of the pathologic changes of AD are seen 
may still be very useful for screening not only pathogenic mechanisms, but also potential drugs 
aimed at, i.e., blocking Mac-1-mediated activation of microglia and subsequent nitric oxide 
release in response to p-amyloid, or any other processes thought to play a role in the 
pathogenesis of Alzheimer's disease. 
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